Article Text

Download PDFPDF

780 Treatment of life-threatening digoxin toxicity with digoxin immune fab antibody: findings from the UK DigiFab®patient registry
  1. Emma Thomas,
  2. Sam Tomlinson,
  3. Siwan Thomas,
  4. Suzanne Ward,
  5. Claire Daugherty,
  6. Eva Gallardo,
  7. Christon Hill
  1. BTG Specialty Pharmaceuticals


Aims/Objectives/Background Digoxin continues to play an important role in the management of atrial fibrillation (AF) and heart failure. Toxicity due to acute over-ingestion of digoxin is generally mild and manageable but can be life-threatening.1 Digoxin immune Fab (DIF; DigiFab®) is the mainstay of treatment for life-threatening digoxin toxicity (LTDT). We report findings on efficacy and safety of DIF from the UK DigiFab Patient Registry.

Methods/Design This prospective, observational study was a post-authorisation requirement from the MHRA. Physicians in all UK hospitals using DIF were invited to submit data for any patient who received DIF for LTDT. All AEs were followed-up according to Good Pharmacovigilance Practice.

Results/Conclusions Between April 2012 and June 2017, 94 patients were enrolled; 10 were excluded (off-label DIF, n=2; outcome not recorded, n=8). Patients were typically elderly (mean: 81 years) and >80% cases involved chronic vs acute toxicity. Most frequently reported symptoms were bradycardia (74%), abnormal mental status/visual disturbance (40%), hyperkalaemia (33%) and gastrointestinal effects (32%). Other cardiac arrhythmias included 2nd/3rd degree heart block (19%), AF (13%), asystole (5%) and ventricular tachycardia (5%); 85% of patients experienced ≥1 arrhythmia. DT resolved in 57 (67.9%) and persisted in 24 (28.6%) patients at the time of reporting. For the remaining 3 (3.6%) patients, the recorded outcome was death. 7 patients reported adverse drugs reactions, including death (n=3) and AF, bradycardia, cardio-respiratory arrest, acute renal failure, cellulitis and hypoglycaemia (all n=1). No cause was reported/established for the 3 deaths and so these were conservatively assessed as possibly related to DIF but were most likely complications of underlying medical conditions. The results were consistent with earlier reports with digoxin-specific antibody Fab fragments,2 with DIF highly effective in resolving LTDT in a real-world setting.


  1. Gummin DD, et al. Clin Toxicol 2020;58:1360–541.

  2. Schaeffer TH, et al. J Am Osteopath Assoc 2010;110:587–92.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.